Background {#Sec1}
==========

*Campylobacter* infection is the leading zoonotic cause of foodborne illness in the world, with 400 million acute cases of diarrheal disease reported worldwide annually \[[@CR1]\]. *C. jejuni* is a leading bacterial cause of human diarrheal infections \[[@CR2], [@CR3]\] in high income countries, but the burden of campylobacteriosis is markedly elevated in low-to-middle income countries (LMIC) and contributes significantly to childhood mortality and poor linear growth in these regions \[[@CR1], [@CR4]--[@CR6]\]. In addition to potentially severe dysentery, campylobacteriosis may also result in longer-term secondary complications including Guillain-Barre syndrome and reactive arthritis \[[@CR1]\]. Antibiotics usually considered for treatment of campylobacteriosis include macrolides and fluoroquinolones (FQs) due to their relatively low cost, limited short-term side effects and ease of administration \[[@CR7]\].

Globally, the emergence of FQ resistance in *C. jejuni* has become a major problem in treating undifferentiated dysentery and campylobacteriosis \[[@CR7]--[@CR10]\]. FQs, including ciprofloxacin, are among the most widely used antibiotics for the treatment of travelers' diarrhea. However, increasing rates of resistance to these drugs have been reported worldwide \[[@CR11]\], with significant treatment implications for the management of *Campylobacter* infections in developing settings with limited access to resources and alternative therapeutic choices \[[@CR12]--[@CR14]\].

The antibacterial activity of ciprofloxacin and other FQs is due to their ability to bind and inhibit the DNA gyrase necessary for genomic DNA replication. Resistance to ciprofloxacin is mediated by mutations in the *gyrA* gene, with the single-step T86I amino acid change as one of the most common mutations associated with decreased susceptibility in *Campylobacter* \[[@CR1], [@CR7]--[@CR10]\]. Alterations of nucleotide 257 (codon 86) from ACA to ATA of the *gyrA* gene result in a threonine to isoleucine substitution in the GyrA protein and confer high- level resistance to ciprofloxacin \[[@CR15]--[@CR20]\].

Numerous molecular techniques based on polymerase chain reaction (PCR) testing may detect mutations associated with resistance to FQ and include sequencing, detection of polymorphisms, and denaturing gradient gel electrophoresis \[[@CR9], [@CR16], [@CR21], [@CR22]\]. In recent years, several of these genotypic methods for the detection of FQ-resistant *Campylobacter* have been validated. To date, all have identified the T86I mutation through nucleic acid amplification \[[@CR17], [@CR23]--[@CR25]\]. However, there are few validation studies among *Campylobacter* isolates from LMICs where rates of antimicrobial resistance (AMR) are particularly high \[[@CR26], [@CR27]\].

The primary goal of this study was to evaluate a RT-PCR assay for detection of the T86I *gyrA* gene mutation among *C. jejuni* isolates from Peru, a middle-income country with rapidly rising rates of FQ-resistant *Campylobacter* \[[@CR27]\] and a substantial burden of campylobacteriosis \[[@CR6], [@CR26]--[@CR28]\].

Methods {#Sec2}
=======

Study sites {#Sec3}
-----------

A surveillance study for AMR in enteric pathogens in Peru occurred between January 2001 to December 2010 at nine hospital and community laboratories in the cities of Lima, Cusco, and Iquitos \[[@CR27]\]. Stool isolates identified as *Campylobacter* spp. were placed in Cary-Blair transport media and stored at 4 °C at the study site \[[@CR27]\]. Every two weeks, isolates from each study site were transported to the U.S. Naval Medical Research Unit No. 6 (NAMRU-6) laboratory at 4 °C for further testing. After microbiological confirmation using routine culture and biochemical methods, all isolates were stored at − 80 °C in Peptone Broth with 15% glycerol.

A random selection of 200 archived stool isolates from children between 1 month to 15 years old during period 2006--2010 were selected from three hospitals in Lima, Peru (Instituto Nacional de Salud del Niño, Hospital Nacional Docente Madre-Niño, and Emergencias Pediatricas) for antimicrobial susceptibility testing and detection of T86I *gyrA* mutation.

Culture and isolation of C. jejuni {#Sec4}
----------------------------------

All archived isolates that were previously identified as hippurate hydrolysis-positive were re-cultured and re-isolated according to methods described elsewhere \[[@CR27]\] for further testing.

Extraction of C. jejuni DNA {#Sec5}
---------------------------

Isolates were reactivated on Columbia agar (Becton, Dickinson and Company, Sparks, MD 21152 USA) that was supplemented with 5% sheep blood after incubation for 48 h at 42 °C under micro-aerobic conditions. One loop of colony growth was then used for DNA extraction which was performed by QIAamp DNA Mini Kit (Qiagen GmbH, D40724 Hilden, Germany), following the manufacturer's guidelines. The final concentration of DNA was adjusted to 10 ng/μl.

Molecular confirmation of C. jejuni species {#Sec6}
-------------------------------------------

*C. jejuni* isolates underwent further species confirmation by PCR. Primers designed by Vandamme et al. \[[@CR29]\] were used to amplify internal *glyA* fragments and detect a 773-bp amplification product consistent with a *C. jejuni* species (Table [1](#Tab1){ref-type="table"}). For PCR reaction, 11 μl of AmpliTaq Gold PCR Master Mix 2X, (AB Applied Biosystems, Foster City, CA 94404, USA), 2 μl of DNA \[10 ng/ μl\] and primers at final concentration of 0.4 μM.DNA were mixed for a final volume of 25 μl. Amplification was performed by Veriti Thermal Cycler (AB Applied Biosystems, Singapore) using the parameters: initial denaturation (5 min 95 °C), twice (1 min 94 °C, 1 min 64 °C, 1 min 72 °C), twice (1 min 94 °C, 1 min 62 °C, 1 min 72 °C), twice (1 min 94 °C, 1 min 60 °C, 1 min 72 °C), twice (1 min 94 °C, 1 min 58 °C, 1 min 72 °C)), twice (1 min 94 °C, 1 min 56 °C, 1 min 72 °C) 30 cycles (1 min 94 °C, 1 min 54 °C, 1 min 72 °C) and final extension step 10 min at 72 °C as recommended by Vandamme et al. \[[@CR29]\]. Post-amplification, PCR products were visualised by 2% UltraPure agarose gel (Invitrogen, Carlsbad, CA 92008, USA) with a SYBR Safe stain (1X) (Invitrogen, Eugene, Oregon, 541.4658300, USA). Table 1Primers and probes usedTarget geneOligonucleotide sequence (5′-3′)Reference*glyA*CATCTTCCCTAGTCAAGCCTVandamme, et al. \[[@CR29]\]AAGATATGGCTCTAGCAAGAC*gyrA*TGCTGTTATAGGTCGTTAThis studyCCTTGTCCTGTAATACTTG*gyrA* Wild typeHEX 5′-CCCACATGGAGATACAGCAGTTTATG-3′-BHQ2This study*gyrA* point mutation T86I6-FAM 5'CCCACATGGAGATATAGCAGTTTATG-3'BHQ1This study*gyrA*GCCTGACGCAAGAGATGGTTBakeli, et al. \[[@CR17]\]TTTGTCGCCATACCTACAGC

Determination of phenotypic resistance {#Sec7}
--------------------------------------

Positively-identified *C. jejuni* isolates were tested for antibiotic susceptibility using the E-test to determine the minimum inhibitory concentration (MIC) for ciprofloxacin at a range of 0.002-32 μg/mL (AB BioMérieux, bioMérieux SA RCS LYON 69280 Marcy-l'Etoile, France) \[[@CR30]\]. Isolates also underwent disk-diffusion testing \[[@CR27]\] using Clinical and Laboratory Standards Institute (CLSI) guidelines to determine susceptibility \[[@CR31]\]. *C. jejuni* ATCC 33560 was used as the quality control organism (American Type Culture Collection, Manassas, Virginia, USA).

Determination of genotypic resistance {#Sec8}
-------------------------------------

A blinded molecular detection of antimicrobial susceptibility was performed on all isolates to generate unbiased results. Isolates were tested for the presence of the T86I *gyrA* resistance mutation using real-time PCR. Specific TaqMan probes and primers (Table [1](#Tab1){ref-type="table"}) were designed by AlleleID 7 software (PREMIER Biosoft International, Palo Alto, California, USA). For a final volume of 20 μl for the PCR reaction, the following were used: 10 μl of Rotor Gene Multiplex PCR (QIAGEN GmbH, Hilden, Germany), 1 μl of DNA \[10 ng/ μl,\] primers, and probes at final concentration of 0.5 μM and 0.25 μM respectively.

DNA amplification and the resultant PCR product was analysed using the Rotor Gene Q version 1.7.94 (QIAGEN GmbH, Hilden, Germany), using the following parameters: pre-denaturation at 95 °C for 5 min, 40 cycles of denaturation at 95 °C for 10 s, annealing at 55 °C for 30 s, and extension at 72 °C for 20 s with acquisition in green and yellow channels.

Detection of ciprofloxacin resistance for allelic discrimination {#Sec9}
----------------------------------------------------------------

Detection of T86I point mutation in the *gyrA* gene of *C. jejuni* was carried out by allelic discrimination. A fluorescent signal from only the HEX dye with acquisition in the yellow channel indicated detection of the wild type (mutation-negative) gene, while the presence of 6-FAM dye fluorescence with acquisition in green channel indicated detection of the T86I mutation (mutation-positive). Absence of both fluorescent signals indicated the gyrA gene was not amplified as observed with *C. jejuni* in no-template controls (NTCs) and *C. coli* isolates. For discrimination of positive and negative mutants, we used a wild-type control (ATCC 33560), a T86I mutant that was identified by sequencing the *gyrA* gene, and a non-template controls for each run, with a threshold of 0.1 for genotypic discrimination. Fluorescent signals were interpreted automatically using sequence detection software using the Rotor Gene Q version 1.7.94 (QIAGEN GmbH, Hilden, Germany).

Validation of T86I gyrA real-time PCR assay diagnostic performance {#Sec10}
------------------------------------------------------------------

Sensitivity and specificity were determined for the T86I *gyrA* resistance mutation real-time PCR assay using disk-diffusion and E-test as gold standards. Confidence intervals (95%) for sensitivity and specificity were determined without continuity correction \[[@CR32], [@CR33]\].

Detection of amino acid mutations in gyrA to confirm PCR results in a subset of isolates {#Sec11}
----------------------------------------------------------------------------------------

Sequencing of the amplified fragment of *gyrA* gene from a random subset of 100 of the 189 *C. jejuni* study isolates were performed to confirm the specific point amino acid mutation T86I in the sequence by, using primers (Table [1](#Tab1){ref-type="table"}) and PCR conditions already described \[[@CR17]\], except that the pre-denaturation time was 1 min and the annealing time was 5 s.

Ethical considerations {#Sec12}
----------------------

The Institutional Review Board of the U.S. Naval Medical Research Unit 6 in Peru (FWA 00010031) determined that the testing of these bacterial isolates (Protocol No PJT.NMRCD.HURS03) did not constitute human subjects research.

Results {#Sec13}
=======

Of the 200 *Campylobacter* isolates, 189 were confirmed as *C. jejuni* and 11 as *C. coli* using biochemical and molecular techniques \[[@CR29]\]. Only the 189 *C. jejuni* isolates were used for the validation study and underwent antimicrobial susceptibility testing.

Phenotypic detection of AMR identified 74.6% (141/189) of the *C. jejuni* isolates as resistant to ciprofloxacin and naldixic acid by disk-diffusion and E-test (Table [2](#Tab2){ref-type="table"}). Further, the molecular detection of the T86I *gyrA* mutation was observed in 100% (141/141) of ciprofloxacin-resistant phenotypes and none of the ciprofloxacin-sensitive phenotypes (Table [3](#Tab3){ref-type="table"}). The T86I *gyrA* mutation detection assay thus demonstrated a sensitivity of 100% (95% CI 97.35--100%) and a specificity of 100% (95% CI 92.6--100%) in comparison to conventional antimicrobial susceptibility testing techniques. Moreover, this assay correctly identified all *C. jejuni* isolates in addition to the ciprofloxacin resistant/sensitive phenotypes, while no *C*. *coli* isolates were detected. Table 2Susceptibility of 189 *C. jejuni* isolates, and point mutation T86I of the *gyrA* genePhenotypeNo. of IsolatesCIP_Disk diffusionNA_Disk diffusionCIP_MICReal-Time PCRRange (mm)Range (mm)Range (μg/mL)***gyrA*** gene (n)CIP-S and NA-S4429--5019--370.008--1.0Wild type 44CIP-R and NA-R1416--116--94--32T86I mutation 141CIP-S and NA-R424--3860.047--0.19Wild type 4*CIP-S* ciprofloxacin sensitive, *CIP-R* ciprofloxacin resistant, *NA-S* nalidixic acid sensitive, *NA-R* nalidixic acid resistant, *MIC* minimal inhibitory concentrationTable 3Comparison of Real Time PCR results with ciprofloxacin antimicrobial susceptibility by E-TestReal Time PCR T86ITotal no. of isolates CIP_MIC_SensitiveTotal no. of isolates CIP_MIC_ResistantWild type (48)480Mutation (141)0141

Seventy-two of the *C. jejuni* isolates that were positive with the T86I PCR assay and 28 of negative wild-type strains were further selected for DNA sequencing of *gyrA* as previously described \[[@CR17]\]. The sequencing results of *gyrA* mutant and wild-type isolates are presented in Table [4](#Tab4){ref-type="table"}. All 72 *C. jejuni* isolates demonstrated amino-acid substitutions at codon 86 (T → I). None of the 28 wild-type isolates demonstrated a point mutation at *gyrA* nucleotide position 257. The amino-acid substitution V149I was also observed in 28 ciprofloxacin resistant isolates as previously reported, with none of the ciprofloxacin-susceptible isolates showing this change. Table [5](#Tab5){ref-type="table"} shows the distribution of *C. jejuni* isolate by hospital and by year, as well as the percentage of those that carried the T86I *gyrA* mutation from 2006 to 2010. Overall, the prevalence of the gene mutation appeared in 65--75% of all isolates for each year until 2010, when it was identified in 100% of all isolates tested. Table 4Correlation between Real-Time PCR T86I mutation MICs values of ciprofloxacin and mutations of the *gyrA* geneReal Time PCR Mutation T86IStrains (***n*** = 100)CIP_MIC (μg/mL)T86IA120VD144NV149IH81G110S119Y152S157V161ACAGCCGATGTTCACGGCAGTTATAGCGTTATAGTCAATATTCATGGTAGCTACAGTGTCPositive2812--32TT----T--C--TCPositive2812--32TT--AT--C--TCPositive732TT----TTC--TCPositive312--32TT----T--CCTCPositive66--32T------------------Negative210.016--0.190--T----T--C--TCNegative10.064--T----TTC--TCNegative10.032--TA--T--C--TCNegative50.023--0.047--------------------Table 5Real time PCR detection of ciprofloxacin sensitive or wild type (WT) *C. jejuni* isolates compared to resistant or T86I positive *C. jejuni* isolates per year by hospitalHospital20062007200820092010T86I (%)WTT86I (%)WTT86I (%)WTT86I (%)WTT86I (%)WTHospital Materno Infantil11 (92)19 (75)31 (25)34 (100)09 (100)0Emergencias Pediátricas12 (63)79 (53)813 (68)613 (65)712 (100)0Hospital del Niño9 (75)316 (76)511 (92)13 (43)49 (100)0**Total32(74)1134(68)1625(72)1020(65)1130(100)0**

Discussion {#Sec14}
==========

Increasing AMR in *C. jejuni* is a major global public health threat. It is important to seek alternatives to conventional phenotypic testing of AMR in *C. jejuni* due to the limited availability of resources to isolate and characterize enteric pathogens in developing countries. This study is one of only a few studies that have validated this method in LMICs, including Latin America.

We have previously described increasing rates of AMR in *Campylobacter* isolates in Peru \[[@CR27]\]. Our data in this study suggest that an increased prevalence of the T86I *gyrA* mutation in *C. jejuni* may be the cause of this rise in FQ resistance (Table [5](#Tab5){ref-type="table"}). The very high sensitivity (100%) and specificity (100%) demonstrated by T86I *gyrA* mutation real-time PCR assay confirms it as a valid alternative resistance assay to conventional fluoroquinolone susceptibility testing in *C. jejuni* isolates, consistent with the high sensitivity and specificity described elsewhere \[[@CR15], [@CR16], [@CR18]\]. This data set may shed light upon the feasibility of this technique to be broadly employed in other regions for detecting changes in ciprofloxacin resistance among *C. jejuni*. Although there are other mutations associated with ciprofloxacin resistance in *gyrA* gene of *C*. *jejuni*, the T86I mutation is the most frequent mutation encountered worldwide \[[@CR17]\]. A different mutation at the same codon, T86A, has also been described in *C. jejuni* isolates with resistance to nalidixic acid \[[@CR16]--[@CR18]\], but its association with resistance to later-generation FQs such as ciprofloxacin is less clear. The present study found no T86A mutations in *C*. *jejuni* isolates through *gyrA* sequencing.

In these Peruvian isolates, the T86I substitution was the main amino-acid change associated with high-level resistance to ciprofloxacin, as described in other settings \[[@CR9], [@CR16], [@CR17], [@CR22], [@CR28]\]. Nonetheless, these findings may be specific to given geographical regions with other common amino-acid substitutions (e.g., V149I) being associated with FQ resistance elsewhere \[[@CR34]\]. However for some of these amino-acid substitutions their relevance as a mediator of AMR have been placed into question with their presence being found in sensitive *C. jejuni* isolates as well as being absent in a large proportion of FQ-resistant isolates \[[@CR17], [@CR28]\]. Until additional characterization studies are performed, questions will remain about the significance of these other mutations in the epidemiology of AMR in *Campylobacter*.

Overall, this technique offers an alternative, reliable, and rapid means for detecting FQ resistance in *C. jejuni* isolates, thus avoiding more complex susceptibility testing for this fastidious microorganism*.* With the recent alarming rise in FQ-resistant *Campylobacter* in Peru \[[@CR6], [@CR27], [@CR35]\], this assay may serve as a useful tool for quality control of conventional *Campylobacter* antibiotic resistance testing, such as disk-diffusion or E-test, in both clinical care and in AMR surveillance.

We utilized E-test strips instead of broth microdilution for confirmatory susceptibility testing, as previously validated \[[@CR36]\]. A limitation of our study was the lack of isolates with intermediate susceptibility to FQs, for which the detection of a molecular determinant of resistance may be useful for antibiogram interpretation, particularly in instances where isolates are non-susceptible to alternative antimicrobials such as macrolides, which has been noted in Peru \[[@CR27]\]. Nonetheless, given the high sensitivity and specificity of the results herein presented, this assay could be a useful tool for the correct identification of *C. jejuni* as well as detection of FQ-resistant isolates from stool samples in developing countries, potentially saving time and money. Additionally, this assay may be applied as a reference control for traditional AMR methods in LMIC where capacities are limited. Given the clinical consequences of this emerging multi-drug resistant phenotype in low-middle income countries, further studies could address the validity and feasibility of molecular methods that simultaneously detect the mutations associated with resistance to both quinolones and macrolides. Effective molecular diagnostics may be a feasible approach to guide the antimicrobial treatment of *C. jejuni* infections.

Conclusions {#Sec15}
===========

The present study developed a rapid, sensitive, and specific molecular technique for the detection of T86I mutations in the *gyrA* gene of *C*. *jejuni* that appears strongly associated with FQ resistance. Because of the high prevalence of *C*. *jejuni* in LMIC and the concern for increasing FQ resistance, this detection approach could be broadly employed in epidemiologic surveillance to reduce time and cost in regions with limited resources.
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